Contemporary Outcomes of Acute Ischemic Stroke in Atrial Fibrillation Patients on Anticoagulation.

BACKGROUND: Long-term anticoagulation (AC) therapy reduces the risk of stroke in patients with Atrial Fibrillation (AF). However, data on the impact of AC on in-hospital stroke outcomes is lacking. METHODS: The National Inpatient Sample was used to identify adult inpatients with AF and a primary diagnosis of ischemic stroke between 2016 and 2020. Data was stratified between AC users and nonusers. A multivariate regression model was used to describe the in-hospital outcomes, adjusting for significant comorbidities. RESULTS: A total of 655,540 hospitalizations with AF and a primary hospitalization diagnosis of ischemic stroke were included, of which 194,560 (29.7%) were on long-term AC. Patients on AC tended to be younger (mean age, 77 vs 78), had a higher average CHA2DS2VASc score (4.48 vs 4.20), higher rates of hypertension (91% vs 88%), hyperlipidemia (64% vs 59%), and heart failure (34% vs 30%) compared to patients not on long-term AC. Use of AC was associated with decreased in-hospital mortality (aOR [95% CI]: 0.62 [0.60 - 0.63]), decreased stroke severity (mean NIHSS, 8 vs 10), decreased use of tPA (aOR 0.42 [0.41 - 0.43]), mechanical thrombectomy (aOR 0.85 [0.83 - 0.87]), intracranial hemorrhage (aOR 0.69 [0.67 - 0.70]), gastrointestinal bleeding (aOR 0.74 [0.70 - 0.77]), and discharge to skilled nursing facilities (aOR 0.90 [0.89 - 0.91]), compared to patients not on AC (P<0.001 for all comparisons). CONCLUSION: Among patients with AF admitted for acute ischemic stroke, AC use prior to stroke was associated with decreased in-hospital mortality, decreased stroke severity, decreased discharge to SNF, and fewer stroke-related and bleeding complications.

Pericardiocentesis Outcomes in Patients With Pulmonary Hypertension: A Nationwide Analysis from the United States.

Pericardiocentesis (PC) in patients with pulmonary hypertension (PH) and pericardial effusions has unclear benefits because it has been associated with acute hemodynamic collapse and increased mortality. Data on in-hospital outcomes in this population are limited. The National Inpatient Sample database was used to identify adult patients who underwent PC during hospitalizations between 2016 and 2020. Data were stratified by the presence or absence of PH. A multivariate regression model and case-control matching was used to estimate the association of PH with PC in-hospital outcomes. A total of 95,665 adults with a procedure diagnosis of PC were included, of whom 7,770 had PH. Patients with PH tended to be older (aged 67 ± 15.7 years) and female (56%) and less frequently presented with tamponade (44.9% vs 52.4%). Patients with PH had significantly higher rates of chronic kidney disease, coronary artery disease, heart failure, and chronic lung disease, among other co-morbidities. In the multivariate analysis, PC in PH was associated with higher all-cause mortality (adjusted odds ratio [aOR] 1.40, confidence interval [CI] 1.30 to 1.51) and higher rates of postprocedure shock (aOR 1.53, CI 1.30 to 1.81) than patients without PH. Mortality was higher in those with pulmonary arterial hypertension than other nonpulmonary arterial hypertension PH groups (aOR 2.35, 95% CI 1.46 to 3.80, p <0.001). The rates of cardiogenic shock (aOR 1.49, 95% CI 1.38 to 1.61), acute respiratory failure (aOR 1.56, 95% CI 1.48 to 1.64), and mechanical circulatory support use (aOR 1.86, 95% CI 1.63 to 2.12) were also higher in patients with PH. There was no significant volume-outcome relation between hospitals with a high per-annum pericardiocentesis volume compared with low-volume hospitals in these patients. In conclusion, PC is associated with increased in-hospital mortality and higher rates of cardiovascular complications in patients with PH, regardless of the World Health Organization PH group.

Impact of Chronic Heart Failure on Acute Pulmonary Embolism in-Hospital Outcomes (From a Contemporary Study).

There is a paucity of evidence on the impact of chronic heart failure (HF) on acute pulmonary embolism (PE) hospitalization outcomes. The aim of this study was to evaluate the in-hospital outcomes of patients with chronic HF and acute PE. A total of 1,391,145 hospitalizations with acute PE from the National Inpatient Sample Database from 2011 to 2019 were included. The database was queried for relevant International Classification of Diseases, Ninth and Tenth Revisions procedural and diagnostic codes. Baseline characteristics and in-hospital outcomes for patients with acute PE were compared in patients with and without a history of chronic HF. Multivariate logistic regression analyses were performed, adjusting for age, race, gender, and statistically significant co-morbidities between cohorts. A p value <0.001 was considered significant. Overall, the mean age was 65.2±16 years; 50.9% of patients were women, and 230,875 patients (16.6%) had chronic HF. The patients in the chronic HF cohort were predominantly older (mean age 69.0 vs 61.4 years) and male (49.9% vs 48.3%). In the multivariate model, chronic HF was associated with increased all-cause mortality (odds ratio [OR] 1.6, 95% confidence interval [CI], 1.57 to 1.63, 10.4% vs 5.7%), acute respiratory distress (OR 1.7, 95% CI 1.70 to 1.74, 39.5% vs 22.1%), cardiac arrest (OR 1.4, 95% CI 1.40 to 1.49, 3.9% vs 2.2%), and cardiogenic shock (OR 3.0, 95% CI 2.85 to 3.06, 4.2% vs 1.2%). All p values were <0.001. In conclusion, patients with PE and chronicHF are associated with increased in-hospital complications compared with patients with PE and without chronic HF. Prospective studies are needed to evaluate optimal management strategies in this population at high risk.

Patient and family engagement in patient care and research in Canadian intensive care units: a national survey.

PURPOSE: While patient and family engagement may improve clinical care and research, current practices for engagement in Canadian intensive care units (ICUs) are unknown. METHODS: We developed and administered a cross-sectional questionnaire to ICU leaders of current engagement practices, facilitators, and barriers to engagement, and whether engagement was a priority, using to an ordinal Likert scale from 1 to 10. RESULTS: The response rate was 53.4% (124/232). Respondents were from 11 provinces and territories, mainly from medical surgical ICUs (76%) and community hospitals (70%). Engagement in patient care included bedside care (84%) and bedside rounds (66%), presence during procedures/crises (65%), and survey completion (77%). Research engagement included ethics committees (36%), protocol review (31%), and knowledge translation (30%). Facilitators of engagement in patient care included family meetings (87%), open visitation policies (81%), and engagement as an institutional priority (74%). Support from departmental (43%) and hospital (33%) leadership was facilitator of research engagement. Time was the main barrier to engagement in any capacity. Engagement was a higher priority in patient care vs research (median [interquartile range], 8 [7-9] vs 3 [1-7]; P < 0.001) and in pediatric vs adult ICUs (10 [9-10] vs 8 [7-9]; P = 0.003). Research engagement was significantly higher in academic vs other ICUs (7 [5-8] vs 2 [1-4]; P < 0.001), and pediatric vs adult ICUs (7 [5-8] vs 3 [1-6]; P = 0.01). CONCLUSIONS: Organizational strategies and institutional support were key facilitators of engagement. Engagement in patient care was a higher priority than engagement in research.

RéSUMé: OBJECTIF: Bien que l'engagement des patients et des familles puisse améliorer les soins cliniques et la recherche, les pratiques actuelles en matière d'engagement dans les unités de soins intensifs (USI) canadiennes sont inconnues. MéTHODE: Nous avons élaboré et administré un questionnaire transversal à l'intention des dirigeants des USI portant sur les pratiques d'engagement actuelles, les facilitateurs et les obstacles à l'engagement, ainsi que la priorisation de l'engagement, en utilisant une échelle de Likert ordinale de 1 à 10. RéSULTATS: Le taux de réponse était de 53,4 % (124/232). Les répondants provenaient de 11 provinces et territoires, principalement d'USI médico-chirurgicales (76%) et d'hôpitaux communautaires (70%). L'engagement dans les soins aux patients comprenait les soins au chevet du patient (84%) et les tournées au chevet (66%), la présence pendant les interventions ou les crises (65%), et la complétion des questionnaires (77%). La participation à la recherche comprenait les comités d'éthique (36%), l'examen des protocoles (31%) et le transfert des connaissances (30%). Les facilitateurs à l'engagement dans les soins aux patients comprenaient les réunions familiales (87%), les politiques de visites ouvertes (81%) et l'engagement en tant que priorité institutionnelle (74%). Le soutien des directions de département (43%) et d'hôpital (33%) a été un facilitateur de l'engagement en recherche. Le temps était le principal obstacle à l'engagement à quelque titre que ce soit. L'engagement était une priorité plus élevée dans les soins aux patients qu'en recherche (médiane [écart interquartile], 8 [7­9] vs 3 [1­7]; P < 0,001) et dans les USI pédiatriques vs adultes (10 [9­10] vs 8 [7­9]; P = 0,003). L'engagement en matière de recherche était significativement plus élevé dans les USI universitaires vs autres (7 [5­8] vs 2 [1­4]; P < 0,001), et pédiatriques vs pour adultes (7 [5­8] vs 3 [1­6]; P = 0,01). CONCLUSION: Les stratégies organisationnelles et le soutien institutionnel ont été des facilitateurs clés de l'engagement. L'engagement dans les soins aux patients était une priorité plus élevée que l'engagement dans la recherche.

Myocardial Fibrosis and Inflammation by CMR Predict Cardiovascular Outcome in People Living With HIV.

OBJECTIVES: The goal of this study was to examine prognostic relationships between cardiac imaging measures and cardiovascular outcome in people living with human immunodeficiency virus (HIV) (PLWH) on highly active antiretroviral therapy (HAART). BACKGROUND: PLWH have a higher prevalence of cardiovascular disease and heart failure (HF) compared with the noninfected population. The pathophysiological drivers of myocardial dysfunction and worse cardiovascular outcome in HIV remain poorly understood. METHODS: This prospective observational longitudinal study included consecutive PLWH on long-term HAART undergoing cardiac magnetic resonance (CMR) examination for assessment of myocardial volumes and function, T1 and T2 mapping, perfusion, and scar. Time-to-event analysis was performed from the index CMR examination to the first single event per patient. The primary endpoint was an adjudicated adverse cardiovascular event (cardiovascular mortality, nonfatal acute coronary syndrome, an appropriate device discharge, or a documented HF hospitalization). RESULTS: A total of 156 participants (62% male; age [median, interquartile range]: 50 years [42 to 57 years]) were included. During a median follow-up of 13 months (9 to 19 months), 24 events were observed (4 HF deaths, 1 sudden cardiac death, 2 nonfatal acute myocardial infarction, 1 appropriate device discharge, and 16 HF hospitalizations). Patients with events had higher native T1 (median [interquartile range]: 1,149 ms [1,115 to 1,163 ms] vs. 1,110 ms [1,075 to 1,138 ms]); native T2 (40 ms [38 to 41 ms] vs. 37 ms [36 to 39 ms]); left ventricular (LV) mass index (65 g/m2 [49 to 77 g/m2] vs. 57 g/m2 [49 to 64 g/m2]), and N-terminal pro-B-type natriuretic peptide (109 pg/l [25 to 337 pg/l] vs. 48 pg/l [23 to 82 pg/l]) (all p < 0.05). In multivariable analyses, native T1 was independently predictive of adverse events (chi-square test, 15.9; p < 0.001; native T1 [10 ms] hazard ratio [95% confidence interval]: 1.20 [1.08 to 1.33]; p = 0.001), followed by a model that also included LV mass (chi-square test, 17.1; p < 0.001). Traditional cardiovascular risk scores were not predictive of the adverse events. CONCLUSIONS: Our findings reveal important prognostic associations of diffuse myocardial fibrosis and LV remodeling in PLWH. These results may support development of personalized approaches to screening and early intervention to reduce the burden of HF in PLWH (International T1 Multicenter Outcome Study; NCT03749343).

Descripción del riesgo cardiovascular en pacientes diabéticos tipo 1 en República Dominicana / Type 1 diabetes cardiovascular risk description in Dominican Republic

Introducción: la diabetes tipo 1 es una enfermedad crónica de alto impacto económico con gran capacidad de ser controlada, la misma no tiene ninguna descripción local previa. Su principal causa de mortalidad es los eventos cardiovasculares y el manejo adecuado la disminuye considerablemente. Objetivo: determinar el riesgo cardiovascular en pacientes adultos con diabetes tipo 1 en la ciudad de Santiago de los Caballeros, República Dominicana. Método: se realizó un estudio descriptivo transversal multicéntrico con 39 pacientes en el período de junio a noviembre de 2019. La calculadora "Steno T1 Risk Engine" se utilizó para estimar el riesgo cardiovascular. Resultados: se obtuvo una relación significativa entre la albuminuria (p = 0.0127), presión arterial sistólica (p = 0.0002), tiempo de diagnóstico (p = 0.0037) y nivel de riesgo cardiovascular. La hemoglobina glucosilada (p = 0,7884) y la actividad física (p = 0.706) no mostraron una relación significativa con el riesgo cardiovascular. Conclusión: el nivel de riesgo cardiovascular promedio es bajo, con probabilidades <10 % de un evento cardiovascular agudo dentro de los 10 años. Esta herramienta permite incluir una evaluación cardiovascular rutinaria con datos que perfilen el tratamiento orientado a disminuir complicaciones vasculares, mortalidad y aumentar adherencia al tratamiento.

Introduction: Type 1 diabetes is a chronic condition with a high economic impact but potentially controllable. There is no previous local description of this condition. Its main fatality cause is due to cardiovascular events and its proper management can diminish it. Objective: This study aimed to determine the cardiovascular risk in adult patients with type 1 diabetes mellitus in the city of Santiago de los Caballeros, Dominican Republic. Method: A descriptive multicenter cross-sectional study was done on 39 patients in the period of June-November 2019. "Steno T1 Risk Engine" calculator estimated the cardiovascular risk. Results: A significant relationship was obtained between albuminuria (p = 0.0127), systolic blood pressure (p = 0.0002), diagnosis time (p = 0.0037) and cardiovascular risk level. Glycated hemoglobin (p = 0.7884) and physical activity (p = 0.7063) did not show a significant relationship with cardiovascular risk. Conclusion: Average cardiovascular risk level is low with <10% probabilities of an acute cardiovascular event within 10 years. This tool could lead to quick cardiovascular risk evaluations to guide the treatment lowering vascular complications, mortality and increasing treatment adherence.

Native T1 and T2 provide distinctive signatures in hypertrophic cardiac conditions - Comparison of uremic, hypertensive and hypertrophic cardiomyopathy.

AIMS: Profound left ventricular (LV) hypertrophy with diastolic dysfunction and heart failure is the cardinal manifestation of heart remodelling in chronic kidney disease (CKD). Previous studies related increased T1 mapping values in CKD with diffuse fibrosis. Native T1 is a non-specific readout that may also relate to increased intramyocardial fluid. We examined concomitant T1 and T2 mapping signatures and undertook comparisons with other hypertrophic conditions. METHODS: In this prospective multicentre study, consecutive CKD patients (n = 154) undergoing routine clinical cardiac magnetic resonance (CMR) imaging were compared with patients with hypertensive (HTN, n = 163) and hypertrophic cardiomyopathy (HCM, n = 158), and normotensive controls (n = 133). RESULTS: Native T1 was significantly higher in all patient groups, whereas native T2 in CKD only (p < 0.001 vs. all groups). Native T1 and T2 were interrelated in patient groups and the strength of association was condition-specific (CKD r = 0.558, HTN r = 0.324, both p < 0.001; HCM r = 0.157, p = 0.05). Native T1 and T2 were similarly correlated in all CKD stages (S3 r = 0.501, S4 0.586, S5 r = 0.424, p < 0.001 for all). Native T1 was the strongest myocardial discriminator between patients and controls (area under the curve, AUC HCM: 0.97; CKD: 0.97, HTN 0.98), native T2 between CKD vs HCM (AUC 0.90) and native T1 and T2 between CKD vs HTN (AUC: 0.83 and 0.80 respectively), p < 0.001 for all. CONCLUSIONS: Our findings reveal different CMR signatures of common hypertrophic cardiac phenotypes. Native T1 was raised in all conditions, indicating the presence of pathologic hypertrophic remodelling. Markedly raised native T2 was CKD-specific, suggesting a prominent role of intramyocardial fluid.